Successful treatment of a patient with Li–Fraumeni syndrome and metastatic lung adenocarcinoma harboring synchronous EGFR L858R and ERBB2 extracellular domain S310F mutations with the pan-HER inhibitor afatinib

References

• Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med 2012; 18:349 - 51; http://dx.doi.org/10.1038/nm.2697; PMID: 22395697
   PubMed Web of Science ®Google Scholar
• Han SW, Kim HP, Shin JY, Jeong EG, Lee WC, Lee KH, Won JK, Kim TY, Oh DY, Im SA, et al. Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. PLoS One 2013; 8:e64271; http://dx.doi.org/10.1371/journal.pone.0064271; PMID: 23700467
   PubMed Web of Science ®Google Scholar
• Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C, O’Meara S, Smith R, Parker A, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004; 431:525 - 6; http://dx.doi.org/10.1038/431525b; PMID: 15457249
   PubMed Web of Science ®Google Scholar
• Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455:1069 - 75; http://dx.doi.org/10.1038/nature07423; PMID: 18948947
   PubMed Web of Science ®Google Scholar
• Bell D, Berchuck A, Birrer M, Chien J, Cramer D, Dao F, Dhir R, DiSaia P, Gabra H, Glenn P, et al, Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609 - 15; http://dx.doi.org/10.1038/nature10166; PMID: 21720365
   PubMed Web of Science ®Google Scholar
• Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, Lee J, Jung YJ, Kim JO, Shin JY, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 2012; 22:2109 - 19; http://dx.doi.org/10.1101/gr.145144.112; PMID: 22975805
   PubMed Web of Science ®Google Scholar
• Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486:395 - 9; PMID: 22495314
   PubMed Web of Science ®Google Scholar
• Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, Chan TL, Kan Z, Chan AS, Tsui WY, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 2011; 43:1219 - 23; http://dx.doi.org/10.1038/ng.982; PMID: 22037554
   PubMed Web of Science ®Google Scholar
• Ali SM, Alpaugh RK, Downing SR, Stephens PJ, Yu JQ, Wu H, Buell JK, Miller VA, Lipson D, Palmer GA, et al. Response of an ERBB2-Mutated Inflammatory Breast Carcinoma to Human Epidermal Growth Factor Receptor 2-Targeted Therapy. J Clin Oncol 2014; Forthcoming http://dx.doi.org/10.1200/JCO.2013.49.0599; PMID: 24516025
   PubMed Web of Science ®Google Scholar
• Johnson BE, Kris MG, Berry LD, Kwiatkowski DJ, Iafrate A J, Varella-Garcia M, Wistuba I I, Franklin W A, Ladanyi M, Su P F, et al. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2013; 31:abstr 8019
   Google Scholar
• Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31:1023 - 31; http://dx.doi.org/10.1038/nbt.2696; PMID: 24142049
   PubMed Web of Science ®Google Scholar
• Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64:8919 - 23; http://dx.doi.org/10.1158/0008-5472.CAN-04-2818; PMID: 15604253
   PubMed Web of Science ®Google Scholar
• Clinical Lung Cancer Genome Project (CLCGP), Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci Transl Med 2013; 5:ra153; PMID: 24174329
   PubMedGoogle Scholar
• Serra V, Vivancos A, Puente XS, Felip E, Silberschmidt D, Caratù G, Parra JL, De Mattos-Arruda L, Grueso J, Hernández-Losa J, et al. Clinical response to a lapatinib-based therapy for a Li-Fraumeni syndrome patient with a novel HER2V659E mutation. Cancer Discov 2013; 3:1238 - 44; http://dx.doi.org/10.1158/2159-8290.CD-13-0132; PMID: 23950206
   PubMed Web of Science ®Google Scholar
• Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013; 31:1997 - 2003; http://dx.doi.org/10.1200/JCO.2012.45.6095; PMID: 23610105
   PubMed Web of Science ®Google Scholar
• Ali SM, Palma NA, Wang K, Ross J S, Stephens P J, Yelensky R, Palmer G A, Lipson D, Miller VA, et al. Clinical next generation sequencing (NGS) to reveal high frequency of alterations to guide targeted therapy in lung cancer patients. J Clin Oncol 2013; 31:abstr 8020
   Google Scholar
• Young G, Wang K, He J, Otto G, Hawryluk M, Zwirco Z, Brennan T, Nahas M, Donahue A, Yelensky R, et al. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. Cancer Cytopathol 2013; 121:688 - 94; http://dx.doi.org/10.1002/cncy.21338; PMID: 23893923
   PubMed Web of Science ®Google Scholar
• Minkovsky N, Berezov A. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs 2008; 9:1336 - 46; PMID: 19037840
   PubMed Web of Science ®Google Scholar
• Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008; 27:4702 - 11; http://dx.doi.org/10.1038/onc.2008.109; PMID: 18408761
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007; 67:11924 - 32; http://dx.doi.org/10.1158/0008-5472.CAN-07-1885; PMID: 18089823
   PubMed Web of Science ®Google Scholar
• Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012; 13:539 - 48; http://dx.doi.org/10.1016/S1470-2045(12)70086-4; PMID: 22452895
   PubMed Web of Science ®Google Scholar
• Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M, Miller VA, Pao W. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008; 14:7519 - 25; http://dx.doi.org/10.1158/1078-0432.CCR-08-0151; PMID: 19010870
   PubMed Web of Science ®Google Scholar
• Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012; 13:528 - 38; http://dx.doi.org/10.1016/S1470-2045(12)70087-6; PMID: 22452896
   PubMed Web of Science ®Google Scholar
• Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat 2012; 133:1057 - 65; http://dx.doi.org/10.1007/s10549-012-2003-y; PMID: 22418700
   PubMed Web of Science ®Google Scholar
• Spicer JF, Rudman SM. EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. Target Oncol 2010; 5:245 - 55; http://dx.doi.org/10.1007/s11523-010-0140-y; PMID: 20574858
   PubMed Web of Science ®Google Scholar
• Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009; 119:3000 - 10; PMID: 19759520
   PubMed Web of Science ®Google Scholar
• Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2012; 2:922 - 33; http://dx.doi.org/10.1158/2159-8290.CD-12-0108; PMID: 22956644
   PubMed Web of Science ®Google Scholar